Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      FDA Approves Belzutifan For Adults With Von Hippel-Lindau Related Cancers

      August 13, 2021
      By Lindsay Fischer
      News
      Article

      Belzutifan, a hypoxia-inducible factor inhibitor, has been approved for treatment of adults with cancers related to von Hippel-Lindau disease.

      FDA Approves Belzutifan For Adults With Von Hippel-Lindau Related Cancers

      FDA Approves Belzutifan For Adults With Von Hippel-Lindau Related Cancers

      The FDA approved belzutifan (Welireg) to treat adult patients with von Hippel-Lindau (VHL)- associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNETs), who do not require immediate surgery, according to a release issued by the agency.

      The regulatory decision was based off updates from the ongoing, open label Study 004 trial (NCT03401788) that evaluated the hypoxia-inducible factor inhibitor in 61 patients with VHL-RCC. To be eligible, patients had to have a VHL germline alteration and at least 1 solid tumor localized to the kidney. Participants with VHL-related tumors like CNS hemangioblastomas and pNETs were also included.

      Patients were administered 120 mg oral belzufitan once daily until progressive disease or intolerable toxicity.

      Primary efficacy end points include overall response rate (ORR), duration of response (DOR), and time-to-response (TTR). ORR will be assessed via radiology assessment and an independent review committee in accordance with RECIST v1.1 criteria. Current data show an ORR of 49% (95% CI, 36-62) for patients with VHL-RCC, 63% for patients with CNS hemangioblastomas, and 83% for patients with measurable pNETs.

      Median DOR has not been reached. Patients with VHL-RCC were followed for a minimum of 18 months from treatment initiation, and 56% of responders experienced a DOR greater or equal to 6 months. The median TTR in this group was 8 months. Among the CNS hemangioblastoma cohort, 73% of responders experienced a DOR of ≥12 months, as did 50% of responsive patients in the pNET group.

      Adverse events (AEs) reported in the study included laboratory abnormalities, decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increase glucose, and nausea. Nurses should be aware that the anemia and hypoxia associated with belzutifan use can be severe. In total, 90% of patients in the study experienced anemia and 7% reported the severity of their anemia to be grade 3. In addition, 1.6 % of patients experienced hypoxia.

      Erythropoiesis stimulating agents are not recommended in patients treated with belzutitfan. Investigators reported that belzutifan renders some hormonal contraceptives infective and that the drug can inflict embryo-fetal harm.

      Reference

      FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. FDA. News release. Accessed August 13, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease?utm_medium=email&utm_source=govdelivery

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Man standing in front of Oncology Nursing News-branded backdrop
      Brenda Martone
      Arash Rezazadeh Kalebasty
      Leapman
      Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
      Related Content

      Photo of the FDA office's sign

      Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

      Bridget Hoyt
      July 2nd 2025
      Article

      Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Image of a laptop with the words "FDA Food and Drug Adminstration" visible

      Oncology Drugs Approved by the FDA in June

      Bridget Hoyt
      July 2nd 2025
      Article

      Oncologic therapies approved in June included indications in genitourinary, lung, and hematologic, and head and neck cancers.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Line illustration of the male genitourinary tract

      Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

      Bridget Hoyt
      June 24th 2025
      Article

      Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.


      Graphic that reads "FDA Approved"

      Dato-DXd Greenlit by FDA for Previously Treated EGFR-Mutated NSCLC

      Bridget Hoyt
      Published: June 23rd 2025 | Updated: June 24th 2025
      Article

      Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy.

      Related Content

      Photo of the FDA office's sign

      Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

      Bridget Hoyt
      July 2nd 2025
      Article

      Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Image of a laptop with the words "FDA Food and Drug Adminstration" visible

      Oncology Drugs Approved by the FDA in June

      Bridget Hoyt
      July 2nd 2025
      Article

      Oncologic therapies approved in June included indications in genitourinary, lung, and hematologic, and head and neck cancers.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Line illustration of the male genitourinary tract

      Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

      Bridget Hoyt
      June 24th 2025
      Article

      Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.


      Graphic that reads "FDA Approved"

      Dato-DXd Greenlit by FDA for Previously Treated EGFR-Mutated NSCLC

      Bridget Hoyt
      Published: June 23rd 2025 | Updated: June 24th 2025
      Article

      Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy.

      Latest Conference Coverage

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.